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on days -1, 0, and 2. Mice were transplanted with T cells and BM
from either syngeneic B6 or allogeneic BALB/c donors. Injection of
SAHA treated DCs resulted in better survival (60% vs. 10%, P 
0.05) and signiﬁcantly reduced serum levels of TNF- and donor T
cell expansion compared to the controls. Together our data demon-
strate a novel IDO dependent mechanism for HDAC inhibitor me-
diated immuno-modulation of DCs and regulation of GVHD.
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DONOR-REACTIVE THYMIC-DEPENDENT TH1 CELLS CAUSE CHRONIC
GVHD
Sakoda, Y.1,2, Hashimoto, D.3, Asakura, S.1, Takeuchi, K.4,
Harada, M.2, Tanimoto, M.1, Teshima, T.3 1Biopathological Science,
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Kyushu University Graduate School of Medical Science, Fukuoka, Japan;
3Center for Cellular and Molecular Medicine, Kyushu University Hos-
pital, Fukuoka, Japan; 4Pathology, Japanese Foundation for Cancer
Institute, Tokyo, Japan.
Chronic graft-versus-host disease (GVHD) continues to be the
most common late complication after allogeneic bone marrow
transplantation (BMT) and the basic pathophysiology of chronic
GVHD remains poorly deﬁned. We have previously demonstrated
that donor bone marrow-derived T cells differentiated via im-
paired thymus of the recipients cause chronic GVHD after allo-
geneic transplantation of T cell-depleted bone marrow (TCD
BM). Lethally irradiated C3H/HeN (H-2k) recipients of TCD BM
cells from MHC class II-deﬁcient (H2Ab1-/-) B6 (H-2b) mice
developed GVHD showing clinical and histopathological features
of human chronic GVHD. We further studied mechanism of
chronic GVHD in this model. A ﬂowcytometric analysis showed
that the numbers of CD4CD25foxp3 regulatory T cells were
comparable between [WT3C3H] and [H2-Ab1-/-3 C3H] mice.
Thymectomy prevented chronic GVHD, thus suggesting the
causal association of the thymus. We then investigated reactivity of
pathogenic CD4 T cells in [H2-Ab1-/- 3 C3H] mice. A ﬂow
cytometric analysis of cell division of CFSE-labeled donor T cells
demonstrated that [H2-Ab1-/- 3 C3H] CD4 T cells divided to
B6 stimulators, but not to C3H stimulators. A ﬂowcytometric
analysis of intracytoplasmic IL-4 and IFN-g suggested polarization
of these cells toward Th1 cytokine responses. Adoptive transfer of
[H2Ab1-/-3 C3H] CD4 T cells caused severe and lethal disease
in B6 recipients. All mice died by day 40 post-BMT and a patho-
logical analysis of the liver and intestine showed standard patho-
logical features of acute GVHD. In contrast, the transfer of [H2-
Ab1-/-3 C3H] CD4 T cells did not cause GVHD in C3H
recipients. Thus, both in vitro and in vivo experiments demon-
strated that these pathogenic CD4 T cells were primarily B6
reactive. Interestingly, the transfer of these cells caused chronic
GVHD in C3H recipients similar to the primary [H2-Ab1-/- 3
C3H] mice in the presence of B6-derived antigen-presenting cells
(APCs). To further conﬁrm the requirement of B6-derived APCs
for the disease, we created [B6 3 C3H] and [C3H 3 C3H]
chimeras. The transfer of [H2-Ab1-/-3 C3H] CD4 T cells did
caused chronic GVHD only in the [B63 C3H] chimeras, but not
in the [C3H 3 C3H] chimeras, thus conﬁrming the requirement
of B6- derived APCs for the transmission of the disease to second-
ary recipients. These results suggest that self-reactivity of donor
Th1 cells play a role in this chronic GVHD.
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THE ALLO-REACTIVITY OF DONOR T-CELLS IS SHAPED BY THE PRES-
ENCE OF IMMUNOSTIMULATORY OR IMMUNOSUPPRESSIVE DONOR
DENDRITIC CELL SUBSETS IN THE GRAFT: IMPLICATIONS FOR GVHD
AND GVL IN BMT
Southerland, L.T.1, Li, J.-M.2, Waller, E.K.2 1Duke University,
Durham, NC; 2Emory University, Atlanta, GA.
The immunological activity of donor T-cells following alloge-
neic BMT is determined by the initial interaction of T-cells with
antigen presenting cells (APC) in the recipient. While previous
reports have established a requirement for host APC in the initi-
ation of GvHD, we have explored the role of donor APC as
positive and negative regulatory elements in the activation of allo-
reactive donor T-cells. We have previously published that alloge-
neic donor BM enriched for CD11b- dendritic cells (DC) pro-
motes enhanced donor T-cell chimerism and GvL, suggesting that
donor DC subsets modulate immune reconstitution post-BMT
(Li, Waller. BBMT 2004). In this study, we examined the immune
polarization capabilities and co-stimulator expression of FACS-
puriﬁed CD11b and CD11b- DC subsets in allogeneic BMT and
their effect on survival, GvL, GvHD, and immune reconstitution.
Fifty thousand puriﬁed CD11b DC or CD11b- DC from
C57BL/6 donors were transplanted along with 5,000 puriﬁed Lin-
,Sca-1,C-kit hematopoietic stem cells (HSC) and 300,000 con-
geneic spleen T-cells into C57BL/6 [H-2Kb] and B10BR [H-2Kk]
recipient mice. The cytokine production, immune proliferation,
and Ki-67 expression of CFSE-labeled donor T-cells were evalu-
ated. Additionally, DC subsets were analyzed by ﬂow cytometry for
co-stimulator expression, including PD-L1, PD-L2, CD80, and
CD86. In tumor free mice, recipients of HSC alone or HSC
combined with CD11b DC or CD11b- DC did not differ in
survival or GvHD over 100 days post allo-BMT. Recipients of
CD11b- DC had increased GvL and donor T-cell proliferation at
days 10, 30, 60, and 105, resulting in full-donor T-cell chimerism.
In contrast, recipients of CD11bDC had mixed T-cell chimerism
and increased numbers of immunosuppressive donor
CD4CD25Foxp3T-cells. Phenotypic and functional analysis
of CD11b and CD11b- DC revealed that CD11b DC had
higher levels of immunosuppressive co-stimulators PD-L1 and
PD-L2, while CD11b- DC induced higher levels of IL-12 and
IFN- when co-cultured with syngeneic T-cells. In conclusion,
donor CD11b- DC promote immune reconstitution and GvL and
polarize donor T-cells to Th1 immune responses, while donor
CD11b DC suppress immune reconstitution by expressing sup-
pressive co-stimulators and promoting tolerant donor Treg cells.












HSC alone 40 none none 90%
HSC alone 20 none LBRM 0%
HSC  T-cells 40 none none 80%
HSC  T-cells 20 none LBRM 0%
HSC  T-cells 
DC 40 CD11b- none 80%
HSC  T-cells 
DC 20 CD11b- LBRM 40%***
HSC  T-cells 
DC 40 CD11b none 80%
HSC  T-cells 
DC 20 CD11b LBRM 0%
HSC5,000 lin-, sca-1, c-kit bone marrow cells; T-cells
300,000 splenic T-cells; DC 50,000 FACS sorted CD11b- or
CD11b dendritic cell subsets; LBRM 100,000 T-lympho-
blastic leukemic cells; *** p0.01 compared to other groups
with LBRM
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PREDICTION OF ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION BY A PRO-
TEOMIC AGVHD-SPECIFIC PATTERN
Weissinger, E.M.1, Schiffer, E.2, Hertenstein, B.1,3, Ferrara, J.L.4,
Holler, E.5, Stadler, M.1, Kolb, H.-J.6, Zander, A.7, Zuerbig, P.2,
Kellmann, M.8, Ganser, A.1 1Hannover Medical School, Hannover,
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Severe, acute graft versus host disease (aGvHD) contributes
signiﬁcantly to morbidity and mortality after allogeneic hemato-
poietic stem cell transplantation (allo-HSCT). Diagnosis of GvHD
is mainly based on clinical features and tissue biopsies, a non
invasive, unbiased laboratory test for GvHD diagnosis does not
exist. To establish such a test, capillary electrophoresis coupled
online with mass spectrometry (CE-MS) was applied to a train-
ingsset consiting of 13 urine samples from 10 allo-HSCT patients
with aGvHD  grade II and 50 urine samples of 23 patients
without GvHD.
Thirty one potential GvHD-speciﬁc polypeptides were chosen
out of 300 differenztially excreted peptides, based on the high
discriminatory values allowing differentiation of patients with
aGvHD from those with no GvHD. This pattern was then used to
characterize urine samples from 141 patients that were collected
prospectively and blinded. The aGvHD speciﬁc model allowed
correct classiﬁcation of 13/13 (sensitivity 100.0 % [95 % CI 75.1 to
100.0]) aGvHD samples and 49/50 (speciﬁcity 98.0 % [95 % CI
89.3 to 99.7]) control samples of the training set. The subsequent
blinded evaluation on 599 samples collected from 141 patients after
allogeneic HSCT enabled the diagnosis of aGvHD  grade II up
to 14 days prior to clinical symptoms with a sensitivity of 81.4%
[95% CI 73.1 to 87.9]) and a speciﬁcity of 75.7 % [95% CI 71.6 to
79.4].
High resolution proteome analysis may help to identify patients
with aGvHD in an unbiased laboratory based screening, possibly
enabling pre-emptive therapy.
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DIFFERENTIAL IMPACT OF MTOR INHIBITION ON FOXP3 REGULA-
TORY T CELLS AS COMPARED TO CONVENTIONAL T CELLS AFTER
ALLOGENEIC BONE MARROW TRANSPLANTATION
Zeiser, R.1, Leveson-Gower, D.B.1, Zambricki, E.A.1, Hou, J.-Z.1,
Negrin, R.1 1Stanford University School of Medicine, Stanford, CA.
FoxP3CD4CD25 regulatory T-cells (Treg) have been
shown to effectively reduce the severity of experimental acute
graft-versus-host disease (aGvHD) while sparing graft-versus-leu-
kemia activity. These ﬁndings, in concert with the observation that
human and murine Treg share functional characteristics, have
fueled interest in clinical trials to control aGvHD. Recent data
indicates that the immunosuppressant rapamycin (RAPA) in con-
trast to cyclosporine A does not interfere with in vivo function of
Treg and could enhance Treg expansion in vitro by a yet unknown
mechanism. To investigate the impact of mTOR inhibition on
proliferating Treg and Tconv, both cell types were stimulated in
the presence of different RAPA concentrations in vitro. Phosphor-
ylation of mTOR downstream products p70S6K1 and 4E-BP1
were assessed by western blot and ﬂow cytometry. Inhibition of the
phosphorylation of p70S6K1 and 4E-BP1 was observed in both
populations in the presence of RAPA. Interestingly, Treg were
more resistant to mTOR inhibition as compared to Tconv and
displayed signiﬁcantly higher phosphorylated products in the pres-
ence of RAPA at 10 nM (MFI Treg vs Tconv, p0.001) and at
100nM (MFI Treg vs Tconv, p0.001). To investigate whether
Treg and RAPA protect from aGvHD in a synergistic manner,
BALB/c recipients were transplanted with H-2 disparate BM and
1.6106 T-cells (FVB/N) after lethal irradiation. aGvHD lethality
was only slightly reduced when suboptimal Tconv:Treg ratios were
employed, or when recipients were treated with a non-protective
RAPA dose (0.5 mg/kg bodyweight). Combining a suboptimal
Tconv:Treg ratio with a non-protective RAPA dose reduced ex-
pansion of luciferase expressing (luc) Tconv and pro-inﬂamatory
cytokines and improved survival indicative for an additive in vivo
effect of RAPA and Treg. To evaluate the impact of RAPA on in
vivo T cell expansion, either luc Tconv or luc Treg were adot-
ively transferred. In vivo bioluminescence imaging demonstrated
that RAPA had a more potent inhibitory effect on proliferation of
Tconv as compared to Treg (p0.05 vs. NS). We did not observe
RAPA to increase FoxP3Treg numbers in vivo. Thus, increased
Treg numbers observed in RAPA containing expansion cultures
are likely due to a lower susceptibility of this cell population to
mTOR inhibition. This could explain the observed synergistic
effect of RAPA and Treg in aGvHD protection which has rele-




HUMAN LEUKOCYTE ANTIGEN (HLA) HAPLOTYPES AND SINGLE HLA
ANTIGENS IN HLA-MATCHED ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (ALLOHSCT) FOR MYELOID DISEASES: ANAL-
YSIS OF OVERALL AND PROGRESSION FREE SURVIVAL (OS/PFS)
Aggarwal, C.1, Gupta, S.1, McCarthy, P.L.2, Battiwalla, M.2,
Hahn, T.E.2 1Department of Medicine, State University of New York at
Buffalo, Buffalo, NY; 2Blood and Marrow Transplant Program, Roswell
Park Cancer Institute (RPCI), Buffalo, NY.
Donor and recipient mismatching in the HLA system is a major
factor inﬂuencing alloHSCT outcome. There is increasing evidence
that speciﬁc HLA antigens inﬂuence immunobiological outcomes
even in HLA-matched alloHSCT. This could be related to the phys-
iological role of the HLA system in differential antigen presentation.
In contrast, HLA haplotypes are associated with multiple immuno-
pathologic diseases by possible inﬂammatory response modulation in
an antigen-independent manner. We recently reported an association
of HLA haplotypes with acute GvHD. We present results of a ret-
rospective review of 119 related and 48 unrelated consecutive ﬁrst
alloHSCT pts treated at RPCI from 1992 to 2003 to investigate the
association of the 3 most common haplotypes in Caucasians
(A1B8DR3, A3B7DR15 and A2B44DR4) and HLA antigens, in ad-
dition to standard transplant risk factors, onOS and PFS. HLA typing
was determined by either molecular (n108) or serologic (n59)
methods. All analyzed patients were matched at HLA-A, -B and
-DRB1 antigen level. Pt characteristics included: 50% AML, 38%
CML and 12% MDS; median age 43 years (range 11-66), 60% 40
years; 62% Male; 95% Caucasian; 73% Recipient-Donor Sex
Match; 78% TBI-containing conditioning regimens; and 88% bone
marrow stem cell source. There were no signiﬁcant differences in pt
characteristics by the presence or absence of each haplotype or anti-
gen. By univariate analysis, HLA-A24 (p0.047) was signiﬁcantly
associated with improved OS whereas HLA-B8 (p0.034), KPS
80 (p0.0045), 40 yrs (p0.0014), and TBI-containing regi-
mens (p0.016) were associated with decreased OS. HLA haplotype
A1B8DR3 trended towards inferior OS (p0.09). Multivariate anal-
ysis found that HLA-B8, age 40 yrs, KPS80 and TBI-contain-
ing regimens were signiﬁcant independent predictors of decreased
OS. Univariate analysis showed that HLA-B8 (p0.0003), -DR3
(p0.026) and A1B8DR3 (p0.028) were signiﬁcantly associated
with inferior PFS. Multivariate analysis found HLA-B8 was the only
signiﬁcant factor associated with decreased PFS. In Caucasians,
HLA-B8 is rarely seen outside the A1B8DR3 haplotype, therefore it
is not possible to distinguish differential antigen presentation from
non-speciﬁc inﬂammation as underlying immunobiologic mecha-
nisms for the survival differences. Larger patient population analyses
are required to differentiate these mechanisms.
Factors inﬂuencing OS and PFS: Mutivariate Analyses





Age > 40 yrs 2.01 1.3-3.2
KPS < 80 1.7 1.1-2.6
TBI based regimen 2.4 1.3-4.4
HLA B8 1.8 1.1-3.0
Significant for inferior PFS
HLA B8 3.6 1.7-7.8
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